Katherine Stueland

Katherine Stueland (chief executive) discloses dealings in 2 companies, chiefly GeneDx Holdings Corp. and Invitae Corp. Over a trading history stretching from 30 April 2021 to 16 September 2026, the count stands at 67 filings.

Both buying and selling appear: 1 purchase worth €96k, against 23 sales worth €5.4M. The totals do not cover 4 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 3 share grants and 40 option exercises. So far in 2026, the count stands at no purchases and 12 sales.

The latest filing, published on 18 September 2026, reports an open-market sale of €128k in GeneDx Holdings Corp. The latest purchase dates back some time: it was published 1,420 days ago, on 28 November 2022. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.